Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations.

Bohn J, Eddings W, Schneeweiss S.

Am J Epidemiol. 2017 Mar 15;185(6):501-510. doi: 10.1093/aje/kww155.

PMID:
28399565
2.

A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.

Gagne JJ, Wang SV, Rassen JA, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):619-27. doi: 10.1002/pds.3616. Epub 2014 Apr 30.

3.

Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.

Gagne JJ, Rassen JA, Choudhry NK, Bohn RL, Patrick AR, Sridhar G, Daniel GW, Liu J, Schneeweiss S.

Drug Saf. 2014 Mar;37(3):151-61. doi: 10.1007/s40264-014-0136-0.

PMID:
24510605
4.

Matching by propensity score in cohort studies with three treatment groups.

Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S.

Epidemiology. 2013 May;24(3):401-9. doi: 10.1097/EDE.0b013e318289dedf.

5.

Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments.

Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim S, Rothman KJ, Liu J, Avorn J.

BMC Med Res Methodol. 2012 Nov 26;12:180. doi: 10.1186/1471-2288-12-180.

6.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

7.

High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications.

Garbe E, Kloss S, Suling M, Pigeot I, Schneeweiss S.

Eur J Clin Pharmacol. 2013 Mar;69(3):549-57. doi: 10.1007/s00228-012-1334-2. Epub 2012 Jul 5.

PMID:
22763756
8.

Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease.

Juillerat P, Schneeweiss S, Cook EF, Ananthakrishnan AN, Mogun H, Korzenik JR.

Aliment Pharmacol Ther. 2012 Aug;36(3):239-47. doi: 10.1111/j.1365-2036.2012.05173.x. Epub 2012 Jun 5.

9.

Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.

Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, Schneeweiss S.

Clin Pharmacol Ther. 2012 Jul;92(1):80-6. doi: 10.1038/clpt.2011.369. Epub 2012 May 16.

10.

Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment.

Polinski JM, Schneeweiss S, Glynn RJ, Lii J, Rassen JA.

Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:90-8. doi: 10.1002/pds.3250.

11.

Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.

Rassen JA, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:41-9. doi: 10.1002/pds.2328.

PMID:
22262592
12.

Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S.

Epidemiology. 2012 Mar;23(2):238-46. doi: 10.1097/EDE.0b013e3182459d7d.

13.

An event-based approach for comparing the performance of methods for prospective medical product monitoring.

Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):631-9. doi: 10.1002/pds.2347. Epub 2012 Jan 4.

14.

Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.

Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA.

Clin Pharmacol Ther. 2011 Dec;90(6):777-90. doi: 10.1038/clpt.2011.235. Epub 2011 Nov 2.

PMID:
22048230
15.

Effects of adjusting for instrumental variables on bias and precision of effect estimates.

Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ.

Am J Epidemiol. 2011 Dec 1;174(11):1213-22. doi: 10.1093/aje/kwr364. Epub 2011 Oct 24.

16.

Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients.

Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, Schneeweiss S.

Am J Epidemiol. 2011 Nov 1;174(9):1089-99. doi: 10.1093/aje/kwr213. Epub 2011 Sep 20.

17.

Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples.

Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S.

Am J Epidemiol. 2011 Jun 15;173(12):1404-13. doi: 10.1093/aje/kwr001. Epub 2011 May 20.

18.

Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.

Margulis AV, Choudhry NK, Dormuth CR, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1088-97. doi: 10.1002/pds.2144. Epub 2011 Apr 28.

19.

A combined comorbidity score predicted mortality in elderly patients better than existing scores.

Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S.

J Clin Epidemiol. 2011 Jul;64(7):749-59. doi: 10.1016/j.jclinepi.2010.10.004. Epub 2011 Jan 5.

20.

A basic study design for expedited safety signal evaluation based on electronic healthcare data.

Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):858-68. doi: 10.1002/pds.1926.

Supplemental Content

Support Center